Sign inCreate account

Report workspace tools

NCT07136792RECRUITINGanonymous

Efficacy and Safety of Pegmolesatide in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI): a Multi-center, Prospective, Open-label, Randomized Parallel Controlled Trial

Sponsor

Source record

Guangdong Provincial People's Hospital

Phase

Source record

Recruiting

Modality

AI-normalized

small molecule

Target

AI-normalized

Pegmolesatide for renal anemia in dialysis patients

Indication / condition

AI-normalized

Renal Anemia of Chronic Kidney Disease

Intervention

Source record

Pegmolesatide 2mg SC, Pegmolesatide 4mg SC, Pegmolesatide 4mg SC, Pegmolesatide 6mg SC

Source & freshness

Source record

NCT ID

NCT07136792

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2026

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07136792

Title

Efficacy and Safety of Pegmolesatide in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI): a Multi-center, Prospective, Open-label, Randomized Parallel Controlled Trial

Sponsor

Guangdong Provincial People's Hospital

Status

RECRUITING

Phase

Recruiting

Condition raw

Renal Anemia of Chronic Kidney Disease

Condition normalized

Renal Anemia of Chronic Kidney Disease

Modality raw

Renal Anemia of Chronic Kidney Disease

Modality normalized

small molecule

Target raw

Pegmolesatide for renal anemia in dialysis patients

Target normalized

Pegmolesatide for renal anemia in dialysis patients

Interventions

Pegmolesatide 2mg SC, Pegmolesatide 4mg SC, Pegmolesatide 4mg SC, Pegmolesatide 6mg SC

Public preview

Source record

This clinical trial evaluates the efficacy and safety of Pegmolesatide, a long-acting erythropoiesis-stimulating agent, in dialysis patients with renal anemia previously treated with HIF-PHIs. The study aims to address the clinical need for effective switching options and establish dosing standards.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Efficacy and Safety of Pegmolesatide in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI): a Multi-center, Prospective, Open-label, Randomized Parallel Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07136792

Status

RECRUITING

Phase

Recruiting

Sponsor

Guangdong Provincial People's Hospital

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy and safety of Pegmolesatide, a long-acting erythropoiesis-stimulating agent, in dialysis patients with renal anemia previously treated with HIF-PHIs. The study aims to address the clinical need for effective switching options and establish dosing standards.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 15, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07136792

Indication

Renal Anemia of Chronic Kidney Disease

Modality

small molecule

Target

Pegmolesatide for renal anemia in dialysis patients

Intervention

Pegmolesatide 2mg SC, Pegmolesatide 4mg SC, Pegmolesatide 4mg SC, Pegmolesatide 6mg SC

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.